NCT00423215 - LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

1,007

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Insulin glargine (LANTUS)

"The patients will receive Lantus administered by subcutaneous injection, once daily at any time but at the same time each day.~Treatment duration: 4 months."

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Netanya